Page 41 - Read Online

Gasparello et al. J Cancer Metastasis Treat 2019;5:52 I http://dx.doi.org/10.20517/2394-4722.2019.17 Page 9 of 11

2008;14:985-90.
7. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res
1977;37:646-50.
8. Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up
of lung cancer patients. Cancer Res 2001;61:4675-8.
9. Spindler KL, Pallisgaard N, Vogelius I Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients
with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 2012;18:1177-85.
10. Perkins G, Yap TA, Pope L, Cassidy AM, Dukes JP, et al. Multi-purpose utility of circulating plasma DNA testing in patients with
advanced cancers. PLoS One 2012;7:e47020.
11. Ignatiadis M, Lee M, Jeffrey SS. Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to
clinical utility. Clin Cancer Res 2015;21:4786-800.
12. Krebs MG, Hou JM, Ward TH, Blackhall FH, Dive C. Circulating tumour cells: their utility in cancer management and predicting
outcomes. Ther Adv Med Oncol 2010;2:351-65.
13. Millner LM, Linder MW, Valdes R. Circulating tumor cells: a review of present methods and the need to identify heterogeneous
phenotypes. Ann Clin Lab Sci 2013;43:295-304.
14. Kuipers EJ, Spaander MC. Personalized screening for colorectal cancer. Nat Rev Gastroenterol Hepatol 2018;15:391-2.
15. Hardingham JE, Grover P, Winter M, Hewett PJ, Price TJ, et al. Detection and clinical significance of circulating tumor cells in colorectal
cancer-20 years of progress. Mol Med 2015;21 Suppl 1:S25-31.
16. Kloten V, Rüchel N, Brüchle NO, Gasthaus J, Freudenmacher N, et al. Liquid biopsy in colon cancer: comparison of different
circulating DNA extraction systems following absolute quantification of KRAS mutations using Intplex allele-specific PCR. Oncotarget
2017;8:86253-63.
17. Thomsen CEB, Appelt AL, Andersen RF, Lindebjerg J, Jensen LH, et al.The prognostic value of simultaneous tumor and serum RAS/
RAF mutations in localized colon cancer. Cancer Med 2017;6:928-36.
18. Veldore VH, Choughule A, Routhu T, Mandloi N, Noronha V, et al. Validation of liquid biopsy: plasma cell-free DNA testing in clinical
management of advanced non- small cell lung cancer. Lung Cancer (Auckl) 2018;9:1-11.
19. Anfossi S, Babayan A, Pantel K, Calin GA. Clinical utility of circulating non-coding RNAs - an update. Nat Rev Clin Oncol
2018;15:541-63.
20. Izzotti A, Carozzo S, Pulliero A, Zhabayeva D, Ravetti JL, et al. Extracellular microRNA in liquid biopsy: applicability in cancer
diagnosis and prevention. Am J Cancer Res 2016;6:1461-93.
21. Huang Z, Huang D, Ni S, Peng Z, Sheng W, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal
cancer. Int J Cancer 2010;127:118-26.
22. Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, et al. Circulating exosomal microRNAs as biomarkers of colon cancer.
PLoS One 2014;9:e92921.
23. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer:
a potential marker for colorectal cancer screening. Gut 2009;58:1375-81.
24. Zheng G, Du L, Yang X, Zhang X, Wang L, et al. Serum microRNA panel as biomarkers for early diagnosis of colorectal adenocarcinoma.
Br J Cancer 2014;111:1985-92.
25. Ghelani HS, Rachchh MA, Gokani RH. MicroRNAs as newer therapeutic targets: a big hope from a tiny player. J Pharmacol
Pharmacother 2012;3:217-27.
26. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010;11:597-610.
27. Gambari R, Fabbri E, Borgatti M, Lampronti I, Finotti A, et al. Targeting microRNAs involved in human diseases: a novel approach for
modification of gene expression and drug development. Biochem Pharmacol 2011;82:1416-29.
28. Piva R, Spandidos D, Gambari R. From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer
research and treatment. Int J Oncol 2013;43:985-94.
29. Gambari R, Brognara E, Spandidos DA, Fabbri E. Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in
the development of miRNA therapeutic strategies in oncology. Int J Oncol 2016;49:5-32.
30. Nishida-Aoki N, Ochiya T. Interactions between cancer cells and normal cells via miRNAs in extracellular vesicles. Cell Mol Life Sci
2015;72:1849-61.
31. Schetter AJ, Okayama H, Harris CC. The role of microRNAs in colorectal cancer. Cancer J 2012;18:244-52.
32. Gheinani AH, Vögeli M, Baumgartner U, Vassella E, Draeger A, et al. Improved isolation strategies to increase the yield and purity of
human urinary exosomes for biomarker discovery. Sci Rep 2018;8:3945.
33. da Silveira JC, Andrade GM, Del Collado M, Sampaio RV, Sangalli JR, et al. Supplementation with small-extracellular vesicles from
ovarian follicular fluid during in vitro production modulates bovine embryo development. PLoS One 2017;12:e0179451.
34. Halvorsen AR, Helland A, Gromov P, Wielenga VT, Talman MM, et al. Profiling of microRNAs in tumor interstitial fluid of breast
tumors - a novel resource to identify biomarkers for prognostic classification and detection of cancer. Mol Oncol 2017;11:220-34.
35. Valentino A, Reclusa P, Sirera R, Giallombardo M, Camps C, et al. Exosomal microRNAs in liquid biopsies: future biomarkers for
prostate cancer. Clin Transl Oncol 2017;19:651-7.
36. Wecker T, Hoffmeier K, Plötner A, Grüning BA, Horres R, et al. MicroRNA Profiling in Aqueous Humor of Individual Human Eyes by
Next-Generation Sequencing. Invest Ophthalmol Vis Sci 2016;57:1706-13.
37. Pu XX, Huang GL, Guo HQ, Guo CC, Li H, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and